Paper340950
Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid.
Wintroub BU and 4 others. N Engl J Med, 1978. Cited by 157 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. Papers, record 340950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/340950
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mast Cells | Major topic |
| Skin | Major topic |
| Skin Diseases, Vesiculobullous | Major topic |
| Autoantibodies | |
| Basement Membrane | |
| Chemotaxis, Leukocyte | |
| Complement C3 | |
| Humans |
Source PubMed
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 157 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,729,378 | Autoimmune Bullous Diseases: Therapeutic Update. | Drugs | 2026 | https://conductscience.org/library/papers/41729378 | PubMed |
| 41,567,205 | The role of immunoglobulin E in non-atopic disorders. | Front Immunol | 2025 | https://conductscience.org/library/papers/41567205 | PubMed |
| 39,932,658 | Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm. | Clin Rev Allergy Immunol | 2025 | https://conductscience.org/library/papers/39932658 | PubMed |
| 39,425,892 | Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review). | Adv Ther | 2024 | https://conductscience.org/library/papers/39425892 | PubMed |
| 36,477,831 | Pruritogens in pemphigoid diseases: Possible therapeutic targets for a burdensome symptom. | J Dermatol | 2023 | https://conductscience.org/library/papers/36477831 | PubMed |
| 36,430,483 | Mast Cells and Interleukins. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430483 | PubMed |
| 36,134,505 | Elevated levels of sCD48 are inversely correlated with markers of disease activity in bullous pemphigoid. | Exp Dermatol | 2023 | https://conductscience.org/library/papers/36134505 | PubMed |
| 35,817,512 | Sex Differences in Mast Cell-Associated Disorders: A Life Span Perspective. | Cold Spring Harb Perspect Biol | 2022 | https://conductscience.org/library/papers/35817512 | PubMed |
| 35,665,207 | Mast cell-deficient mice Mcpt5Cre/Dicer fl/fl redefine the role of mast cells in experimental bullous pemphigoid. | Skin Health Dis | 2022 | https://conductscience.org/library/papers/35665207 | PubMed |
| 34,200,214 | May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature. | Microorganisms | 2021 | https://conductscience.org/library/papers/34200214 | PubMed |
| 31,297,118 | Proteases in Pemphigoid Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31297118 | PubMed |
| 29,731,653 | Histologic characterization of cellular infiltration in autoimmune subepidermal bullous diseases in a tertiary hospital in Saudi Arabia. | Clin Cosmet Investig Dermatol | 2018 | https://conductscience.org/library/papers/29731653 | PubMed |
| 29,545,809 | The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. | Front Immunol | 2018 | https://conductscience.org/library/papers/29545809 | PubMed |
| 29,541,076 | The Role of Mast Cells in Autoimmune Bullous Dermatoses. | Front Immunol | 2018 | https://conductscience.org/library/papers/29541076 | PubMed |
| 28,496,445 | Eosinophils in Autoimmune Diseases. | Front Immunol | 2017 | https://conductscience.org/library/papers/28496445 | PubMed |
| 25,944,979 | Mast cell and autoimmune diseases. | Mediators Inflamm | 2015 | https://conductscience.org/library/papers/25944979 | PubMed |
| 25,400,334 | Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis. | Mediators Inflamm | 2014 | https://conductscience.org/library/papers/25400334 | PubMed |
| 25,062,998 | Mast cell function: a new vision of an old cell. | J Histochem Cytochem | 2014 | https://conductscience.org/library/papers/25062998 | PubMed |
| 24,954,907 | Omalizumab therapy for bullous pemphigoid. | J Am Acad Dermatol | 2014 | https://conductscience.org/library/papers/24954907 | PubMed |
| 24,845,463 | Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. | Immunol Res | 2014 | https://conductscience.org/library/papers/24845463 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/340950
GET https://conductscience.org/api/papers/v1/340950/cited_by?page=2